S-Gboxin
产品说明书
 |
同义名 : | - |
| CAS号 : | 2101317-21-7 | |
| 货号 : | A1149112 | |
| 分子式 : | C27H32F3IN2O2 | |
| 纯度 : | 98% | |
| 分子量 : | 600.45 | |
| MDL号 : | MFCD31813866 | |
| 存储条件： |
Pure form Inert atmosphere, 2-8°C In solvent -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : | - | |
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | Glioblastoma (GBM) is the most aggressive and prevalent primary malignancy of the central nervous system. S-Gboxin, a functional analog of gboxin, specifically inhibits primary mouse and human GBM cell growth with an IC50 value of 470 nM. Antitumor activity was first assessed by daily S-Gboxin treatment at 10 mg/kg/day beginning on day 3 or day 14 after mouse GBM (HTS cells) allograft flank implantation. S-Gboxin treated mice showed reduced tumor volume, cellular density, proliferation, and enhanced survival in comparison to vehicle controls. S-Gboxin treated tumors had reduced expression of the high-grade glioma makers, GFAP and Olig2. Primary human GBM cells were also injected into flanks of immunocompromised mice in the presence of matrigel. After visible tumors were detected (3 days) S-Gboxin was administered daily (10 mg/kg/day) resulting in significant attenuation of growth and decreased cellular density compared to controls. Further, S-Gboxin treatment (2.16 μg/day/mouse) inhibited tumor growth as manifested by reduced hemorrhaging, cellular density, and decreased proliferation. Histopathology analysis further showed reduced expression of the high-grade glioma makers. Moreover, S-Gboxin demonstrated inhibition of GBM PDX growth as manifested by general health status, reduced cellular density, cellular proliferation, and GBM marker expression[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.67mL 0.33mL 0.17mL |
8.33mL 1.67mL 0.83mL |
16.65mL 3.33mL 1.67mL |
| 参考文献 |
|---|